Sami Saba, MD
Neurology · Livingston, NJNPI 1932491339
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.1% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $698, 7.3 times the $96 reported in 2019. That places this record below the midpoint for neurology clinicians in NJ, where the typical reported total is $1,560.
Across 36 payments — averaging $25.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$165
- AstraZeneca$157
- Biogen$103
- CSL Behring$100
- Genentech USA, Inc.$92
- AbbVie$63
- plus $255 from 12 others
Across 7 payments — averaging $17,988 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$126K
What the payments were for
- Food & beverage$88094%
- Education$556%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 4 | $165 |
| AstraZeneca(2 entities) | 3 | $157 |
| Biogen | 5 | $103 |
| CSL Behring | 3 | $100 |
| Genentech USA, Inc. | 5 | $92 |
| AbbVie | 3 | $63 |
| Catalyst Pharmaceuticals, Inc. | 1 | $28 |
| GE HealthCare | 2 | $28 |
| Abbott | 1 | $25 |
| Misonix Inc | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Pfizer | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| UCB, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$935 in reported general payments places this provider in the 40th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 49 | $418,189 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 13 | $320,463 |
| Radicava OrsEdaravone | 15 | $215,546 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 11 | $163,184 |
| AptiomEslicarbazepine Acetate | 11 | $13,083 |
| Pyridostigmine Bromide | 47 | $4,332 |
| Pregabalin | 89 | $2,745 |
| Gabapentin | 107 | $1,812 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 42 | $1,165 |
| Levetiracetam | 23 | $989 |
| Duloxetine Hcl | 20 | $779 |
| Prednisone | 79 | $657 |
| Mycophenolate Mofetil | 27 | $543 |
| Zonisamide | 13 | $448 |
| Propranolol Hcl | 11 | $349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $20 | $418,18949 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 521 neurology providers in New Jersey.
Other neurology in Livingston
- Matthew TremblayLivingston$35K
- Yanchun ZhangLivingston$35K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.